In the intermediate stage (BCLC-B), the magnitude of the tumor burden may be quite heterogeneous, and prognosis is also influenced by AFP concentration and the degree of liver function impairment even if still belonging to Child–Pugh class A. This individualized patient profile may also determine whether liver transplantation, transarterial chemoembolization (TACE), or systemic therapy should be used. This evidence concerns the gene AFP and neoplasm.